🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchPhase 3 trial enrollment guide — how to participate in GLP-1 studies Page 2

Phase 3 trial enrollment guide — how to participate in GLP-1 studies

TrialTracker_MD Sat, May 30, 2026 at 9:28 AM 10 replies 430 viewsPage 2 of 2
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
May 31, 2026 at 5:27 PM#6
TrialTracker_MD said:
The gap between trial results and real-world results is consistent and it is not fraud.
TrialTracker_MD said:
...regarding the trial evidence...

I think this is an underappreciated point. To expand on it with some data:

A recent meta-analysis of 12 RCTs (n=8,400) found that the trial evidence was associated with a significant effect size across diverse patient populations[1].

The NNT was 8, which is comparable to statins for secondary prevention. That's a strong clinical argument for this approach.

Last edited: May 31, 2026 at 7:27 PM
13 16TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 10 others
Reply Quote Save Share Report
maria_elpaso
Member
312
1,456
Sep 2024
El Paso, TX
Jun 1, 2026 at 6:13 AM#7

A narrower follow-up, since the general answer is now clear:

What would you measure differently if you were starting again?

14 17RunnerRach, TrialNerd_Beth, HPLC_Greg and 11 others
Reply Quote Save Share Report
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Jun 1, 2026 at 6:58 PM#8
labquiet_amy said:
TrialTracker_MD said: ...regarding the trial evidence...

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 12,000 GLP-1 users vs matched controls showed reduced heart failure hospitalization (HR 0.74) over 3 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
Last edited: Jun 2, 2026 at 12:58 AM
15 18james_edin, FranDenver, Dr.BariatricHTX and 12 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Jun 2, 2026 at 7:43 AM#9

OP back with an update, since a thread like this is useless without one.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

Last edited: Jun 2, 2026 at 12:43 PM
16 19Dr.PulmRoch, maya_sedona, stefan_berlin and 13 others
Reply Quote Save Share Report
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Jun 4, 2026 at 8:54 PM#10
Dr.LeslieOBGYN said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:

  1. Point estimate (HR/RR/OR) — center of the diamond
  2. Confidence interval width — precision of the estimate
  3. I² statistic — heterogeneity across studies
  4. Individual study weights — are results driven by one large trial?
  5. Prediction interval — range of plausible true effects in future settings

The the trial evidence meta-analysis shows a pooled RR of 0.75 (95% CI 0.69-0.90), I²=48%. This is a robust and consistent effect.

Last edited: Jun 5, 2026 at 12:54 AM
16 16dan_philly, MeganSA_TX, LarryQC_SD and 13 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register